Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 1/20 | 0.33 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.33 |
| ▸ | PDE9A | O76083 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9901421 | 0.87 | EPHX2 (0.36) | GAAKMT2A | |
| SCHEMBL9902706 | 0.86 | KCNQ3 (0.35) | KCNQ3KCNQ2KDM4EGAAKMT2A | |
| SCHEMBL9902803 | 0.86 | GAA (0.41) | KCNQ3KCNQ2PDE9AGRM4KDM4E | |
| SCHEMBL9901731 | 0.81 | KDM4E (0.35) | KCNQ3KCNQ2PDE9AGRM4KDM4E | |
| SCHEMBL17271379 | 0.81 | KCNJ11 (0.34) | KCNQ3KCNQ2 | |
| SCHEMBL16994509 | 0.81 | KCNJ11 (0.34) | KCNQ3KCNQ2 | |
| SCHEMBL9901676 | 0.80 | TSHR (0.40) | KDM4EKMT2A | |
| SCHEMBL9902746 | 0.79 | OPRM1 (0.37) | KDM4EKMT2A | |
| SCHEMBL9901704 | 0.79 | EPHX2 (0.36) | GAA | |
| SCHEMBL9901787 | 0.79 | GAA (0.43) | KDM4EGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649048-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | Radikal Therapeutics Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012077108-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | RADIKAL THERAPEUTICS INC. (US) | 2012-06-14 | — | — | WO | disclosed |